Brooks Laboratories Share Price & Announcements

Quick check

The five things to look at first. Open one for more.

Compared with its industry

Brooks Laboratories against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.

Valuation (P/E)57.2 against a typical 33.1: pricier than most peers (1st = cheapest).163rd of 221
Sales growth−17.4% against a typical +17.4% from a year earlier.175th of 199
Profit growth+750% against a typical +22.2% from a year earlier.6th of 162
Share price, 3 months+2.5% against a typical +2.6%.103rd of 204
Size₹ 188.7 Cr. market value against a typical ₹ 484.8 Cr. (1st = largest).121st of 203

Latest announcements

Exchange filings and their impact on the company.

7 Nov 2026Outcome of Board MeetingHigh impactVery positivePrice +4.3% on 8 Nov

Rs 74.7 cr stake-sale gain drives record profit and cash pile despite 14% sales fall.

AIAI analysisVery positive for shareholdersHigh impact

Rs 74.7 cr stake-sale gain drives record profit and cash pile despite 14% sales fall.

Brooks Laboratories reported Q2 FY27 standalone revenue of Rs 19.25 cr, down 18% from last year, and H1 revenue of Rs 42.21 cr. It sold 11.48% of its joint venture Brooks Steriscience for Rs 74.74 cr, booking a Rs 74.7 cr exceptional gain. This lifted H1 consolidated net profit to Rs 65.82 cr and bank balances to Rs 64.12 cr, though the retained 37.52% JV share made a Rs 5.58 cr loss.

Why it matters: Partial divestment of 11.48% in Brooks Steriscience for Rs 74.74 cr creates Rs 74.7 cr exceptional gain, ~87% of FY26 sales and ~42% of market cap, lifting H1 net profit to Rs 65.8 cr and bank balances to Rs 64.1 cr while core Q2 revenue fell 18% YoY.

For shareholders: One-off Rs 74.7 cr cash gain and stronger balance sheet dwarf weak core sales and JV losses for shareholders.

Estimated effect over the next 12 months

Estimated effect over the next 12 months
Metric	Now	Estimated change	Confidence
Revenue	₹ 86 Cr. FY26 year ended Mar 2026	▼ −15% to −8% · −₹ 12.9 Cr. to −₹ 6.88 Cr. H1 FY27 revenue Rs 42.21 cr down 13.8% YoY and Q2 down 18% YoY; annualizing implies ~Rs 75 cr in next 12 months vs Rs 86 cr baseline	70%
Operating margin	8% FY26 year ended Mar 2026	▼ −4 pts to −2 pts Q2 segment margin ~3.1% vs 9.5% prior year and H1 profit before JV/tax Rs 2.02 cr on Rs 42.21 cr sales; full-year margin likely 4-6% vs 8% baseline	65%
Net profit	₹ 25 Cr. FY26 year ended Mar 2026	▲ +150% to +190% · +₹ 37.5 Cr. to +₹ 47.5 Cr. Rs 74.7 cr exceptional gain on BSL stake sale already booked in H1; H1 consolidated net profit Rs 65.82 cr vs Rs 17.56 cr prior H1, so reported 12-month profit ~Rs 62-72 cr vs Rs 25 cr baseline	90%
EPS	₹ 8.35 FY26 year ended Mar 2026	▲ +156% to +180% · +₹ 13 to +₹ 15 H1 consolidated EPS Rs 22.35 already exceeds full FY26 EPS Rs 8.35 due to Rs 74.7 cr gain on 2.95 cr shares; full 12-month EPS likely Rs 21-23	90%
Net debt	₹ 19.29 Cr. LFY as of 2026-08-20 context	▼ −389% to −337% · −₹ 75 Cr. to −₹ 65 Cr. Rs 74.74 cr cash consideration received, Rs 64.12 cr parked in bank balances at Sep 2026 and Rs 1.78 cr net debt repaid; net debt turns to large net cash	85%
Market cap	₹ 176.37 Cr. 2026-10-29 market data	▲ +20% to +40% · +₹ 35.27 Cr. to +₹ 70.55 Cr. Rs 74.7 cr cash gain equals ~42% of market cap and lifts book value ~55%; assume market capitalizes part of cash buffer despite weak core sales	50%
Working capital	34 days FY26 working capital days 34 days	▲ +14.7% to +29.4% · +5 to +10 Sep 2026 receivables up to Rs 18.06 cr from Rs 16.11 cr at Mar 2026 and payables down, while sales fell; cash conversion likely stretches 5-10 days	55%
Capex	₹ 16 Cr. FY26 fixed assets Rs 15 cr plus CWIP Rs 1 cr	▲ +12.5% to +25% · +₹ 2 Cr. to +₹ 4 Cr. H1 purchase of PPE Rs 2.72 cr and CWIP up to Rs 1.98 cr at Sep 2026; assume continued small maintenance capex Rs 2-4 cr funded from sale proceeds	60%
Net worth	₹ 122 Cr. FY26 equity Rs 29 cr plus reserves Rs 93 cr	▲ +53.3% to +61.5% · +₹ 65 Cr. to +₹ 75 Cr. Consolidated equity already Rs 188.48 cr at Sep 2026 vs Rs 122.66 cr at Mar 2026 due to Rs 65.82 cr H1 profit including Rs 74.7 cr gain less Rs 5.58 cr JV loss	90%

Generated by AI from the original document. It can be wrong or incomplete and is not investment advice. Check the source before acting on it. Estimates are rough projections, not forecasts by Minerva Capital Research Solutions.

Brooks Laboratories reported Q2 FY27 standalone revenue of Rs 19.25 cr, down 18% from last year, and H1 revenue of Rs 42.21 cr. It sold 11.48% of its joint venture Brooks Steriscience for Rs 74.74 cr, booking a Rs 74.7 cr exceptional gain. This lifted H1 consolidated net profit to Rs 65.82 cr and bank balances to Rs 64.12 cr, though the retained 37.52% JV share made a Rs 5.58 cr loss.

Filing

14 Oct 2026Outcome of Board MeetingLow impactPositivePrice +2.5% on 15 Oct

Board approved demerger of manufacturing business with 97% of sales into WOS for separate listing on 1:1 basis.

AIAI analysisPositive for shareholdersLow impact

Board approved demerger of manufacturing business with 97% of sales into WOS for separate listing on 1:1 basis.

Brooks Laboratories' board on October 14, 2026 approved demerger of its Baddi manufacturing business, which was Rs 82.87 crore or 96.66% of FY26 turnover, into its wholly-owned Abridge Speciality Limited. Shareholders will get 1 share of Abridge for every 1 share held, and Abridge will seek listing on BSE and NSE, with the two companies to be renamed Brooks Laboratories and Xuri Lifesciences respectively. The scheme needs stock exchange, SEBI, NCLT and shareholder approvals over an indicative 16-month timeline, creating two focused trading and manufacturing platforms with no cash consideration.

Why it matters: Board on Oct 14, 2026 approved demerger of Manufacturing Business (Rs 82.87 cr, 96.66% of FY26 turnover) into wholly-owned Abridge Speciality for 1:1 listing; NCLT/SEBI approvals guide effectiveness in 10-13 months and listing in 13-16 months, so next-12-month consolidated operations are unchanged except for transaction costs.

For shareholders: 1:1 tax-neutral split preserves shareholders' economic interest while creating focused platforms and listing optionality, outweighing near-term scheme costs and approval risk.

Estimated effect over the next 12 months

Estimated effect over the next 12 months
Metric	Now	Estimated change	Confidence
Revenue	₹ 86 Cr. FY26	0% · +₹ 0 Cr. Demerged undertaking Rs 82.87 cr is 96.66% of FY26 turnover, but stays consolidated until Effective Date guided at months 10-13; 12 months to Oct-27 largely pre-effectiveness so consolidated revenue unchanged	85%
Operating margin	8% FY26	▼ −1 pts to −0.5 pts Rs 0.5-1.0 cr scheme, valuation, legal and NCLT costs on ~Rs 86 cr revenue = 0.6-1.2pp drag, with no operating separation yet	60%
Net profit	₹ 25 Cr. FY26	▼ −4% to −2% · −₹ 1 Cr. to −₹ 0.5 Cr. Rs 0.5-1.0 cr transaction costs expensed with no tax benefit assumed = -2% to -4% on FY26 PAT of Rs 25 cr which included Rs 20 cr other income	60%
EPS	₹ 8.34 FY26	▼ −4% to −2% · −₹ 0.34 to −₹ 0.17 Rs 0.5-1.0 cr cost / ~2.95 cr shares outstanding implied by 29457248 shares to be issued 1:1 = Rs 0.17-0.34 EPS drag	60%
Net debt	₹ 9 Cr. Mar 2026	0% · +₹ 0 Cr. No cash consideration and no new borrowing disclosed; presentation notes ~Rs 50 cr capital availability each side but no debt raise in next 12 months	80%
Net worth	₹ 122 Cr. Mar 2026	0% · +₹ 0 Cr. 1:1 issue by wholly-owned Abridge with cancellation of 10000 shares held by parent; net assets stay in group until effectiveness, only drag is expensed scheme costs	80%

Generated by AI from the original document. It can be wrong or incomplete and is not investment advice. Check the source before acting on it. Estimates are rough projections, not forecasts by Minerva Capital Research Solutions.

Brooks Laboratories' board on October 14, 2026 approved demerger of its Baddi manufacturing business, which was Rs 82.87 crore or 96.66% of FY26 turnover, into its wholly-owned Abridge Speciality Limited. Shareholders will get 1 share of Abridge for every 1 share held, and Abridge will seek listing on BSE and NSE, with the two companies to be renamed Brooks Laboratories and Xuri Lifesciences respectively. The scheme needs stock exchange, SEBI, NCLT and shareholder approvals over an indicative 16-month timeline, creating two focused trading and manufacturing platforms with no cash consideration.

Filing

Credit ratings

Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates

Agency	Current rating	Outlook	As of
CARE	—	Stable	12 Nov 2026

Rating

12 Nov 2026

▲ Upgrade1 notch

—

High

CARE

₹ 12 Cr.

AIAI analysisVery positive for shareholdersHigh impact

Rating details

Rating: —
Instruments: Fund-based - LT-Cash Credit; Non-fund-based - ST-BG/LC
Source: CARE rationale

CARE upgraded Brooks to BB+/A4+ after Rs 106 cr stake sale made it net debt free.

CARE upgraded Brooks Laboratories long-term bank facilities to BB+ Stable from BB and short-term to A4+ from A4 on Rs 12 cr facilities. The upgrade follows receipt of Rs 106.33 cr from selling a 16.33% stake in Brooks Steriscience, which makes the company net debt free and cut corporate guarantee exposure to Rs 48.15 cr from Rs 116.77 cr. CARE noted FY26 operating margin improved to 8.88% and guided 10-11% ahead, with a proposed demerger of manufacturing into Abridge Speciality.

Why it matters: Rs 106.33 cr divestment proceeds (~56% of Rs 188.65 cr market cap and ~87% of Rs 122 cr net worth) makes company net debt free, cuts adjusted gearing from 4.12x and funds capex, with margins guided to 10-11%.

For shareholders: Rs 106.33 cr cash wipes out debt, halves guarantee exposure and funds growth internally.

Estimated effect over the next 12 months

Estimated effect over the next 12 months
Metric	Now	Estimated change	Confidence
Revenue	₹ 86 Cr. FY26 (Mar 2026)	▲ +12% to +21% · +₹ 10 Cr. to +₹ 18 Cr. CARE TOI Rs 86.26 cr in FY26 targeting Rs 150 cr by FY29 with 10-11% margins; ~15-20% growth in next 12 months on capacity and export recovery -> +Rs 10-18 cr on FY26 sales Rs 86 cr	55%
Operating margin	8% FY26	▲ +1.5 pts to +2.5 pts PBILDT 8.88% in FY26 per CARE vs 6.03% in FY25; agency guides 10-11% on better mix and manufacturing share -> +1.5-2.5pp on 8% FY26 OPM	60%
Net profit	₹ 25 Cr. FY26 (Mar 2026)	▲ +12% to +24% · +₹ 3 Cr. to +₹ 6 Cr. operating leverage on +Rs 10-18 cr revenue at 10-11% margin plus lower interest after becoming net debt free -> +Rs 3-6 cr recurring on FY26 PAT Rs 25 cr	50%
EPS	₹ 8.34 FY26 (Mar 2026)	▲ +12% to +24% · +₹ 1 to +₹ 2 same profit uplift on ~2.9 cr shares with no dilution indicated -> +Rs 1-2 on FY26 EPS Rs 8.34	50%
Net debt	₹ 19.29 Cr. LFY (FY26)	▼ −130% to −100% · −₹ 25 Cr. to −₹ 19.29 Cr. Rs 106.33 cr cash received repays Rs 7-9 cr borrowings leaving company net debt free per CARE -> wipes out Rs 19.29 cr LFY net debt plus small net cash	85%
Market cap	₹ 188.65 Cr. 2026-11-05	▲ +15% to +30% · +₹ 28.3 Cr. to +₹ 56.6 Cr. Rs 106 cr cash (~56% of market cap) de-risks balance sheet cuts guarantees and funds capex internally; partial re-rating -> +15-30% on Rs 188.65 cr market cap	50%
Working capital	34 days FY26	▼ −29% to −15% · −10 to −5 cash surplus lowers reliance on working capital limits (60-70% utilisation) and funds operations internally -> -5 to -10 days on 34 days FY26 working capital days	45%
Capex	₹ 16 Cr. Mar 2026 (Fixed assets Rs 15 cr + CWIP Rs 1 cr)	▲ +250% to +375% · +₹ 40 Cr. to +₹ 60 Cr. major capacity expansion to be funded entirely from Rs 106.33 cr divestment surplus with no term debt; assume Rs 40-60 cr spent in next 12 months vs Rs 16 cr fixed assets+CWIP base	45%
Net worth	₹ 122 Cr. Mar 2026 (Equity Rs 29 cr + Reserves Rs 93 cr)	▲ +57% to +74% · +₹ 70 Cr. to +₹ 90 Cr. Rs 106.33 cr consideration less book value of 16.33% stake in Brooks Steriscience plus retained profits lifts tangible net worth; assume Rs 70-90 cr net accretion on Rs 122 cr Mar-26 net worth	60%

Generated by AI from the original document. It can be wrong or incomplete and is not investment advice. Check the source before acting on it. Estimates are rough projections, not forecasts by Minerva Capital Research Solutions.

11 Nov 2025

Reaffirmed

CARE BB

—

CARE

₹ 12 Cr.

Board meetings

Results dates and other board meetings. Full calendar

		Details
7 Nov 2026	Financial Results	To consider and approve the financial results for the period ended September 30, 2026
13 Aug 2026	Financial Results	To consider and approve the financial results for the period ended Jun 30, 2026
29 May 2026	Financial Results	To consider and approve the financial results for the period ended March 31, 2026
6 Feb 2026	Financial Results	To consider and approve the financial results for the period ended December 31, 2025
14 Nov 2025	Financial Results	To consider and approve the Half Yearly Unaudited Financial results of the Company for the period ended 30 September 2025 and Other business
13 Aug 2025	Financial Results	To consider and approve the financial results for the period ended Jun 30, 2025 and other business.

Share price

1M change −1.17%

1 of 2 filing days came with a big price moveBiggest +2.5% on 15 Oct 2026AI reading matched the move 1 of 1

Volume (shares)Price (₹)

Close priceFiling moves (1)Other filings (1)Volume

Financials

Consolidated figures in ₹ crore.

Quarterly results
₹ Cr.	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026
Sales	22	18	18	21	21	23	26	23	17	20	23	19
Expenses	25	27	20	24	22	25	22	21	16	20	24	21
Operating Profit	−3	−10	−2	−3	−2	−1	3	3	1	1	−1	−2
OPM %	−15%	−54%	−11%	−16%	−7%	−5%	12%	11%	4.4%	3.4%	−6%	−11%
Other Income	0	1	0	0	0	1	7	6	5	1	0	76
Interest	0	0	0	0	0	0	0	0	0	0	0	0
Depreciation	0	0	0	0	0	0	0	0	0	0	0	0
Profit before tax	−4	−10	−2	−4	−2	−1	10	8	6	2	−2	73
Tax %	1%	0%	0%	0%	0%	14%	0%	0%	0%	0%	0%	7%
Net Profit	−4	−10	−2	−4	−2	−1	10	8	6	2	−2	68
EPS in Rs	−1.48	−3.66	−0.92	−1.51	−0.81	−0.5	3.25	2.71	1.87	0.52	−0.61	22.95
YoY Sales growth	42	41	14	−15	−6	32	42	13	−19	−13	−10	−18

Growth and returns

Compounded yearly rates over each period.

Compounded Sales Growth

10 Years: —
5 Years: 2%
3 Years: 11%
TTM: −15%

Compounded Profit Growth

10 Years: —
5 Years: 27%
3 Years: 47%
TTM: −75%

Stock Price CAGR

10 Years: −7%
5 Years: −11%
3 Years: −19%
TTM: —

Return on Equity

10 Years: —
5 Years: −9%
3 Years: −2%
TTM: —

Shareholding

Latest: Sep 2026.

Promoters

52.62%

0 pts in a year

FIIs

0.04%

+0.03 pts in a year

DIIs

10.5%

+0.12 pts in a year

Public

36.84%

−0.16 pts in a year

P/E and EPS over time

Daily P/E and trailing 12-month EPS. EPS updates with each result.

P/E 57.2xEPS (12 months) ₹ 1.17Median P/E 13.6x

P/E (times)EPS (₹)